Literature DB >> 19683559

Trop2: a possible therapeutic target for late stage epithelial carcinomas.

Rafael Cubas1, Min Li, Changyi Chen, Qizhi Yao.   

Abstract

Trop2 is a cell-surface glycoprotein overexpressed in a variety of late stage epithelial carcinomas with low to no expression in normal tissues. Some of the important roles that Trop2 plays in epithelial cancers have recently been revealed. Trop2 overexpression is associated with decreased patient survival as well as increased tumor aggressiveness and metastasis. Its overexpression in metastatic tissue makes it a very attractive and potential therapeutic target for late stage disease. This protein can transduce an intracellular calcium signal and contains a conserved phosphatidylinositol 4,5-bisphosphate (PIP(2)) binding motif as well as a serine phosphorylation site which interacts with protein kinase C. This protein has recently being found to be expressed in cells with stem-like properties which allude to a potential role in progenitor cell biology. Further understanding of the signaling pathways involved with this molecule and its important role in metastasis will shed new light on the mechanism of Trop2 overexpression in late stage disease and could result in the development of new therapies targeting this widely overexpressed oncogene.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19683559     DOI: 10.1016/j.bbcan.2009.08.001

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  57 in total

1.  Chemotherapy agents-induced immunoresistance in lung cancer cells could be reversed by trop-2 inhibition in vitro and in vivo by interaction with MAPK signaling pathway.

Authors:  Xi Wang; Min Long; Ke Dong; Fang Lin; Yuanyuan Weng; Yongri Ouyang; Li Liu; Junxia Wei; Xi Chen; Ting He; Hui-Zhong Zhang
Journal:  Cancer Biol Ther       Date:  2013-09-04       Impact factor: 4.742

2.  Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody.

Authors:  Joyce Varughese; Emiliano Cocco; Stefania Bellone; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Thomas J Rutherford; Natalia Buza; Sergio Pecorelli; Alessandro D Santin
Journal:  Am J Obstet Gynecol       Date:  2011-07-13       Impact factor: 8.661

3.  Trophoblast cell surface antigen 2 (Trop-2) phosphorylation by protein kinase C α/δ (PKCα/δ) enhances cell motility.

Authors:  Yugo Mori; Kaoru Akita; Kazuki Ojima; Shungo Iwamoto; Tomoko Yamashita; Eiichi Morii; Hiroshi Nakada
Journal:  J Biol Chem       Date:  2019-06-07       Impact factor: 5.157

4.  First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors.

Authors:  Alexander N Starodub; Allyson J Ocean; Manish A Shah; Michael J Guarino; Vincent J Picozzi; Linda T Vahdat; Sajeve S Thomas; Serengulam V Govindan; Pius P Maliakal; William A Wegener; Steven A Hamburger; Robert M Sharkey; David M Goldenberg
Journal:  Clin Cancer Res       Date:  2015-05-05       Impact factor: 12.531

5.  Different effects of ERβ and TROP2 expression in Chinese patients with early-stage colon cancer.

Authors:  Yu-Jing Fang; Guo-Qiang Wang; Zhen-Hai Lu; Lin Zhang; Ji-Bin Li; Xiao-Jun Wu; Pei-Rong Ding; Qing-Jian Ou; Mei-Fang Zhang; Wu Jiang; Zhi-Zhong Pan; De-Sen Wan
Journal:  Tumour Biol       Date:  2012-09-29

6.  CD27 enhances the killing effect of CAR T cells targeting trophoblast cell surface antigen 2 in the treatment of solid tumors.

Authors:  Huanpeng Chen; Fengjiao Wei; Meng Yin; Qingyu Zhao; Zhonghua Liu; Bolan Yu; Zhaofeng Huang
Journal:  Cancer Immunol Immunother       Date:  2021-01-13       Impact factor: 6.968

7.  Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

Authors:  Aditya Bardia; Ingrid A Mayer; Jennifer R Diamond; Rebecca L Moroose; Steven J Isakoff; Alexander N Starodub; Nikita C Shah; Joyce O'Shaughnessy; Kevin Kalinsky; Michael Guarino; Vandana Abramson; Dejan Juric; Sara M Tolaney; Jordan Berlin; Wells A Messersmith; Allyson J Ocean; William A Wegener; Pius Maliakal; Robert M Sharkey; Serengulam V Govindan; David M Goldenberg; Linda T Vahdat
Journal:  J Clin Oncol       Date:  2017-03-14       Impact factor: 44.544

8.  Trop2 gene: a novel target for cervical cancer treatment.

Authors:  Xiaoqi Liu; Siqi Li; Faping Yi
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-10       Impact factor: 4.553

9.  TROP2 correlates with microvessel density and poor prognosis in hilar cholangiocarcinoma.

Authors:  Shanglei Ning; Sen Guo; Jianjun Xie; Yunfei Xu; Xiaofei Lu; Yuxin Chen
Journal:  J Gastrointest Surg       Date:  2012-12-01       Impact factor: 3.452

10.  Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma.

Authors:  Ning Xu; Zhihong Zhang; Jin Zhu; Lu Xu; Yuhua Li; Lei Duan; Yuan Mao; Hongxia Li
Journal:  Int J Exp Pathol       Date:  2016-04-29       Impact factor: 1.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.